ES2495666B1 - Uso de derivados con enlaces c-o-p en pacientes con fallo renal - Google Patents

Uso de derivados con enlaces c-o-p en pacientes con fallo renal Download PDF

Info

Publication number
ES2495666B1
ES2495666B1 ES201330383A ES201330383A ES2495666B1 ES 2495666 B1 ES2495666 B1 ES 2495666B1 ES 201330383 A ES201330383 A ES 201330383A ES 201330383 A ES201330383 A ES 201330383A ES 2495666 B1 ES2495666 B1 ES 2495666B1
Authority
ES
Spain
Prior art keywords
patients
renal failure
derivatives
links
bonds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201330383A
Other languages
English (en)
Other versions
ES2495666R1 (es
ES2495666A2 (es
Inventor
Joan Perelló Bestard
Carolina Salcedo Roca
Miquel David FERRER REYNÉS
Bernat Isern Amengual
Pieter H. JOUBERT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoris Sanifit SL
Original Assignee
Laboratoris Sanifit SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES201330383A priority Critical patent/ES2495666B1/es
Application filed by Laboratoris Sanifit SL filed Critical Laboratoris Sanifit SL
Priority to BR112015023509A priority patent/BR112015023509A2/pt
Priority to CN201480021589.1A priority patent/CN105611913A/zh
Priority to AU2014229971A priority patent/AU2014229971B2/en
Priority to JP2015562269A priority patent/JP6571538B2/ja
Priority to RU2015139225A priority patent/RU2725626C2/ru
Priority to EP14716875.1A priority patent/EP2974714A1/en
Priority to CA2906264A priority patent/CA2906264C/en
Priority to MX2015013088A priority patent/MX2015013088A/es
Priority to CN202111218422.2A priority patent/CN114010649A/zh
Priority to PCT/ES2014/070184 priority patent/WO2014140402A1/es
Publication of ES2495666A2 publication Critical patent/ES2495666A2/es
Publication of ES2495666R1 publication Critical patent/ES2495666R1/es
Application granted granted Critical
Publication of ES2495666B1 publication Critical patent/ES2495666B1/es
Priority to HK16108972.7A priority patent/HK1220898A1/zh
Priority to AU2019201988A priority patent/AU2019201988B2/en
Priority to JP2019146292A priority patent/JP6863618B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de derivados con enlaces C-O-P en pacientes con fallo renal.#Uso para el tratamiento de pacientes con fallo renal en forma de liberación controlada de un derivado con enlaces C-O-P. Además comprende el uso de dichos compuestos derivados junto con otros principios activos, que particularmente se pueden seleccionar de la lista que comprende un calcimimético, vitamina, quelante de fósforo, tiosulfato, bifosfonato, pirofosfato, citrato, un diurético, antihipertensivo y anticolesterolémico.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
–
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
ES201330383A 2013-03-15 2013-03-15 Uso de derivados con enlaces c-o-p en pacientes con fallo renal Active ES2495666B1 (es)

Priority Applications (14)

Application Number Priority Date Filing Date Title
ES201330383A ES2495666B1 (es) 2013-03-15 2013-03-15 Uso de derivados con enlaces c-o-p en pacientes con fallo renal
PCT/ES2014/070184 WO2014140402A1 (es) 2013-03-15 2014-03-14 Uso de derivados con enlaces c-o-p en pacientes con fallo renal
AU2014229971A AU2014229971B2 (en) 2013-03-15 2014-03-14 Use of derivatives with C-O-P bonds in patients with renal failure
JP2015562269A JP6571538B2 (ja) 2013-03-15 2014-03-14 腎不全を患っている患者におけるｃ−ｏ−ｐ結合を含む誘導体の使用
RU2015139225A RU2725626C2 (ru) 2013-03-15 2014-03-14 Применение производных, содержащих связи с-о-р, у пациентов с почечной недостаточностью
EP14716875.1A EP2974714A1 (en) 2013-03-15 2014-03-14 Use of derivatives with c-o-p bonds in patients with renal failure
CA2906264A CA2906264C (en) 2013-03-15 2014-03-14 Use of derivatives with c-o-p bonds in patients with renal failure
MX2015013088A MX2015013088A (es) 2013-03-15 2014-03-14 Uso de derivados con enlaces c-o-p en pacientes con fallo renal.
BR112015023509A BR112015023509A2 (pt) 2013-03-15 2014-03-14 uso de derivados com ligações c-o-p em pacientes com insuficiência renal
CN201480021589.1A CN105611913A (zh) 2013-03-15 2014-03-14 包含c-o-p键的衍生物在患有肾功能衰竭的患者中的用途
CN202111218422.2A CN114010649A (zh) 2013-03-15 2014-03-14 包含c-o-p键的衍生物在患有肾功能衰竭的患者中的用途
HK16108972.7A HK1220898A1 (zh) 2013-03-15 2016-07-27 包含 鍵的衍生物在患有腎功能衰竭的患者中的用途
AU2019201988A AU2019201988B2 (en) 2013-03-15 2019-03-22 Use Of Derivatives With C-O-P Bonds In Patients With Kidney Failure
JP2019146292A JP6863618B2 (ja) 2013-03-15 2019-08-08 腎不全を患っている患者におけるｃ−ｏ−ｐ結合を含む誘導体の使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201330383A ES2495666B1 (es) 2013-03-15 2013-03-15 Uso de derivados con enlaces c-o-p en pacientes con fallo renal

Publications (3)

Publication Number Publication Date
ES2495666A2 ES2495666A2 (es) 2014-09-17
ES2495666R1 ES2495666R1 (es) 2014-10-30
ES2495666B1 true ES2495666B1 (es) 2015-08-10

Family

ID=50478876

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201330383A Active ES2495666B1 (es) 2013-03-15 2013-03-15 Uso de derivados con enlaces c-o-p en pacientes con fallo renal

Country Status (11)

Country Link
EP (1) EP2974714A1 (es)
JP (2) JP6571538B2 (es)
CN (2) CN105611913A (es)
AU (2) AU2014229971B2 (es)
BR (1) BR112015023509A2 (es)
CA (1) CA2906264C (es)
ES (1) ES2495666B1 (es)
HK (1) HK1220898A1 (es)
MX (1) MX2015013088A (es)
RU (1) RU2725626C2 (es)
WO (1) WO2014140402A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016013737A1 (de) 2016-11-17 2018-05-17 WindplusSonne GmbH Hexahydroxycyclohexanhexaphosphorsäureestersalze zur Behandlung von Kalzinose sowie diätische Lebensmittel mit Hexahydroxycyclohexanhexaphosphorsäureestersalzen als Zusatzstoffe
JP7118635B2 (ja) * 2017-12-20 2022-08-16 Ｅａファーマ株式会社 医薬用組成物
EP3556728A1 (en) * 2018-04-16 2019-10-23 Croda Denmark A/S Organically modified mineral micro-particles, methods of preparing the same and uses thereof
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3917535A1 (en) * 2019-01-30 2021-12-08 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in increasing tissular perfusion
EP3818983A1 (en) * 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5330979A (en) * 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
SU1435255A1 (ru) * 1986-10-20 1988-11-07 Московский медицинский стоматологический институт им.Н.А.Семашко Способ восстановлени противотромбогенной активности сосудистой стенки у кардиологических больных
IT1306133B1 (it) * 1999-04-22 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina ed un inositolfosfato, utilequale integratore dietetico o medicamento.
DE29910454U1 (de) * 1999-06-10 1999-09-23 Vitasyn GmbH, 10789 Berlin Mittel zur Therapie von Hyperphosphatämie
ES2232302B1 (es) * 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2332636B1 (es) * 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.

Also Published As

Publication number Publication date
ES2495666R1 (es) 2014-10-30
AU2014229971B2 (en) 2019-04-04
CA2906264C (en) 2021-05-11
JP2019206580A (ja) 2019-12-05
AU2014229971A1 (en) 2015-11-05
BR112015023509A2 (pt) 2017-07-18
ES2495666A2 (es) 2014-09-17
HK1220898A1 (zh) 2017-05-19
WO2014140402A1 (es) 2014-09-18
JP6571538B2 (ja) 2019-09-04
AU2019201988B2 (en) 2021-04-08
RU2015139225A (ru) 2017-04-24
CN114010649A (zh) 2022-02-08
CA2906264A1 (en) 2014-09-18
AU2019201988A1 (en) 2019-04-11
MX2015013088A (es) 2016-04-18
EP2974714A1 (en) 2016-01-20
JP2016514119A (ja) 2016-05-19
CN105611913A (zh) 2016-05-25
RU2725626C2 (ru) 2020-07-03
JP6863618B2 (ja) 2021-04-21

Similar Documents

Publication Publication Date Title
ES2495666B1 (es) Uso de derivados con enlaces c-o-p en pacientes con fallo renal
EP3427310A4 (en) SUPERCONDUCTING HYPER FREQUENCY INTERCONNECTION HOLES FOR MULTIPLANA QUANTUM CIRCUITS
CY1121929T1 (el) Ενωσεις δεσμευσης νηε3 και μεθοδοι για την αναστολη μεταφορας φωσφορικου
UY34313A (es) ?Composición herbicida que comprende micropartículas poliméricas que contienen un herbicida y método para la reducción del efecto antagonista?.
JP2014515038A5 (es)
CL2015000408A1 (es) Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer.
HUE056724T2 (hu) Zsírsav sókon alapuló rovarölõ/atkaölõ készítmény
AR098024A1 (es) Fármaco para la prevención y/o tratamiento de la poliquistosis renal
FR3012814B1 (fr) Composition polymere comprenant et liberant un compose actif odorant
FR3050664B1 (fr) Systeme d'evaluation in vitro de l'efficacite d'un deodorant.
BR112017026807A2 (pt) agentes solubilizantes para compostos ativos funcionais
ES2600132T9 (es) Procedimiento para la preparación de estructuras oligoméricas complejas
FR3054997B1 (fr) Systeme et procede d'accrochage d'une charge, telle que notamment une embarcation de sauvetage, permettant un largage rapide de la charge
ES2533758B1 (es) Composición que comprende albúmina para su utilización en el tratamiento de cirrosis descompensada
UY35544A (es) Complejos de bis azainositol hafnio para adquisición de imágenes por rayos x
CL2019002174A1 (es) Composición que comprende capecitabina de liberación inmediata y liberación prolongada.
ES1214209Y (es) Piso para calzado monocomponente.
CN302140526S (zh) 鞋柜
BR112017010912A2 (pt) formulação para a liberação efetiva de tocotrienol
CN302455422S (zh) 不间断电源(gxe 1kva ups 长机)
BR112017021044A2 (pt) agente terapêutico para o olho seco compreendendo nandrolona ou éster da mesma ou metenolona ou éster da mesma como um ingrediente ativo
CN302414460S (zh) 不间断电源(gxe 1kva ups 标机)
TH1401007019A (th) 5-อะมิโน[1,4]ไธอะซีน (5-Amino[1,4]Thiazine) ในรูปสารยับยั้ง BACE 1
CN301979809S (zh) 禽畜笼
CN302489027S (zh) 不间断电源(ups 二)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2495666

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150810